Effect of Epigallocatechin Gallate supplementation on type 2 diabetes

Effects of Epigallocatechin Gallate Supplementation on the Insulin Resistence and Inflammatory Factors in Patients with Type 2 Diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181219042047N1

Enrollment

Registered

2019-02-13

Start date

2018-12-11

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: All patients will receive 300 mg (2×150mg) epigallocatechin Gallate capsules for 8 weeks. Intervention 2: Control group: All patients will receive 300 mg (2×150 mg)

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Men or women aged between 20 to 60 years old, Minimum 2 years experience in diabetes.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Alcohol consumption; Smoking; Pregnant and lactating women; Injection insulin; Taking anti inflammatory drugs; Using nutrition supplements; Hormone Therapy; Patients with a history of hypothyroidism; Renal failure.

Design outcomes

Primary

Measure	Time frame
High sensitive C reactive protein. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Fasting Blood Sugar (FBS). Timepoint: Before and after 8 weeks intervention. Method of measurement: Mg/dl, laboratory kit.;Insulin. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Insulin Resistance (IR). Timepoint: Before and after 8 weeks intervention. Method of measurement: Based on HOMA IR equation.;Body Mass Index (BMI). Timepoint: Before and after 8 weeks intervention. Method of measurement: Weight (kilograms) divided by the square of height (meters).	—

Measure

Time frame

High sensitive C reactive protein. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Fasting Blood Sugar (FBS). Timepoint: Before and after 8 weeks intervention. Method of measurement: Mg/dl, laboratory kit.;Insulin. Timepoint: Before and after 8 weeks intervention. Method of measurement: ELISA.;Insulin Resistance (IR). Timepoint: Before and after 8 weeks intervention. Method of measurement: Based on HOMA IR equation.;Body Mass Index (BMI). Timepoint: Before and after 8 weeks intervention. Method of measurement: Weight (kilograms) divided by the square of height (meters).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaid hadi

Artesh University of Medical Sciences

s.hadinu@yahoo.com+98 21 4382 2284

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026